Analysing non-synonymous mutations in XDR and MDR tuberculosis drugs

Pallavi Surana; Ashwin Kumar Jainarayanan; Nithishwer Mouroug Anand; Mukta Sharma

doi:10.1016/j.jctube.2019.100124

Analysing non-synonymous mutations in XDR and MDR tuberculosis drugs

J Clin Tuberc Other Mycobact Dis. 2019 Sep 19:17:100124. doi: 10.1016/j.jctube.2019.100124. eCollection 2019 Dec.

Authors

Pallavi Surana¹, Ashwin Kumar Jainarayanan^{2

3}, Nithishwer Mouroug Anand², Mukta Sharma³

Affiliations

¹ R.V. College of Engineering, Bengaluru, India.
² Indian Institute of Science Education and Research, Mohali, India.
³ CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.

Abstract

Tuberculosis is a bacterial disease caused by Mycobacterium tuberculosis. It is known to be the second-largest cause of death and models a severe risk to public health throughout the world. Though it affects people of almost every age, individuals with weakened immune systems, (e.g., HIV infection) are more likely to get infected. The present study deals with analyzing non-synonymous mutations in anti-tuberculosis drugs, which may have a significant role in causing XDR and MDR tuberculosis drug resistance. Continued use of tuberculosis drugs, discontinuation of medicines and various other factors can promote drug resistance in the host's body. To understand the actual cause of resistance, we have identified some patterns of mutations which might be responsible for a change in the structure of the protein, ultimately causing drug resistance. Here, we aim to present some of the unique mutation patterns in the genes associated with the marketed drugs that might have a deleterious effect. In this study, we have used molecular docking approach for understanding the ligand binding affinity of the mutated drugs. The results are further validated by molecular dynamics studies.

Keywords: MDR; Molecular docking; Molecular dynamics; Non-synonymous mutations; Tuberculosis; XDR.